SCHEMBL17023897

SCHEMBL17023897

c1ccc(-c2nc(-c3ccc(-c4nc(-c5ccccn5)n5ccccc45)s3)c3ccccn23)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
MAPT P10636 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 3/20 0.50
GLA P06280 2/20 0.50
HIF1A Q16665 3/20 0.45
EPAS1 Q99814 3/20 0.45
GAA P10253 6/20 0.43
POLB P06746 2/20 0.43
BRD4 O60885 1/20 0.41
BRD2 P25440 1/20 0.41
BRD3 Q15059 1/20 0.41
BAZ2B Q9UIF8 1/20 0.41
BAZ2A Q9UIF9 1/20 0.41
MAP2K3 P46734 1/20 0.40
MAPK14 Q16539 1/20 0.40
PTGS2 P35354 1/20 0.39
HTT P42858 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17023882 0.85 HIF1A (0.47) KDM4EMAPTNPC1RAB9AGLA
SCHEMBL17023904 0.84 KDM4E (0.47) KDM4EMAPTNPC1HIF1AGAA
SCHEMBL17023894 0.84 GAA (0.50) KDM4EMAPTNPC1HIF1AEPAS1
SCHEMBL17023877 0.82 GAA (0.46) KDM4EMAPTNPC1HIF1AEPAS1
SCHEMBL25787087 0.82 KMT2A (0.56) KDM4EMAPTNPC1HIF1AEPAS1
SCHEMBL17023905 0.82 BRD4 (0.43) KDM4EMAPTNPC1HIF1AEPAS1
SCHEMBL17023881 0.80 GAA (0.47) KDM4EMAPTNPC1HIF1AEPAS1
SCHEMBL17023872 0.80 BRD4 (0.41) KDM4EMAPTNPC1RAB9AHIF1A
SCHEMBL17023893 0.79 HIF1A (0.59) KDM4EMAPTNPC1RAB9AHIF1A
SCHEMBL22406353 0.79 BRD4 (0.44) KDM4EMAPTNPC1RAB9AGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10847726-B2 Imidizo derivatives THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2020-11-24 US disclosed
US-10847726-B2 Imidizo derivatives THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2020-11-24 US disclosed
US-20190131538-A1 IMIDIZO DERIVATIVES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2019-05-02 US disclosed
US-20190131538-A1 IMIDIZO DERIVATIVES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2019-05-02 US disclosed
US-20150243896-A1 IMIDAZO DERIVATIVES ARMY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2015-08-27 US disclosed
US-20150243896-A1 IMIDAZO DERIVATIVES ARMY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2015-08-27 US disclosed
US-20150243896-A1 IMIDAZO DERIVATIVES ARMY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190131538-A1 IMIDIZO DERIVATIVES IKZF1, IKZF3, IKZF2 KDM4E 1297/4885MAPT 2630/4885NPC1 4706/4885
US-10847726-B2 Imidizo derivatives IKZF1, IKZF3, IKZF2 KDM4E 1297/4885MAPT 2630/4885NPC1 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.